Manan Shah, MD
Neurocritical Care · Augusta, GANPI 1376897645
Payments from drug & device makers
What this record shows
24 manufacturers reported payments, led by Astrazeneca UK Limited at 54.6% of the total. Reporting peaked in 2022 at $1,746 and has fallen 86.8% since, to $231 in 2025.
Across 64 payments — averaging $46.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$2K
- Chiesi USA, Inc.$167
- SK Life Science, Inc.$146
- Stryker$146
- Takeda Pharmaceuticals U.S.A., Inc.$140
- UCB, Inc.$139
- plus $610 from 18 others
Across 3 payments — averaging $20,635 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$62K
What the payments were for
- Travel & lodging$1,47850%
- Food & beverage$1,49250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 9 | $1,621 |
| Chiesi USA, Inc. | 4 | $167 |
| SK Life Science, Inc. | 5 | $146 |
| Stryker | 1 | $146 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $140 |
| UCB, Inc. | 6 | $139 |
| Jazz Pharmaceuticals Inc. | 5 | $115 |
| AstraZeneca | 4 | $76 |
| Pfizer | 3 | $59 |
| CSL Behring | 2 | $48 |
| Genentech USA, Inc. | 3 | $41 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $39 |
| Biogen | 1 | $29 |
| Amgen | 1 | $28 |
| Azurity Pharmaceuticals, Inc. | 1 | $24 |
| Harrow Eye, LLC | 1 | $23 |
| Greenwich Biosciences, Inc. | 1 | $23 |
| Ceribell, Inc. | 1 | $20 |
| Olympus America Inc. | 1 | $20 |
| Novartis | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Medtronic | 1 | $16 |
| Natus Medical Incorporated | 1 | $11 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few neurocritical care providers in Georgiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurocritical care in Augusta
- Samuel TsappidiAugusta$54K
- Klepper GarciaAugusta$997
- Manjunath MarkandayaGainesville$12K
- Anand SarmaAtlanta$2K
- Christopher HornMarietta$897
- Andres RuizGainesville$486
- Anantha VellipuramAtlanta$361
- Joao Mc-Oneil PlancherMarietta$314
- Starane ShepherdAtlanta$268
- Muthu BhaskaranAtlanta$235
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.